Compare EVTV & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTV | RDHL |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 3.9M |
| IPO Year | 2017 | N/A |
| Metric | EVTV | RDHL |
|---|---|---|
| Price | $0.41 | $1.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 75.2K |
| Earning Date | 11-20-2025 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,696,856.00 | ★ $9,550,000.00 |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 113.69 | ★ 157.62 |
| 52 Week Low | $0.45 | $1.01 |
| 52 Week High | $14.30 | $7.30 |
| Indicator | EVTV | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 15.88 | 47.48 |
| Support Level | $0.75 | $1.15 |
| Resistance Level | $1.37 | $1.24 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 1.10 | 33.66 |
Envirotech Vehicles Inc is a provider of purpose-built zero-emission electric vehicles focused on reducing the total cost of vehicle ownership and helping fleet operators unlock the benefits of green technology. It recognizes revenue from the sales of zero-emission electric vehicles and vehicle maintenance and inspection services. The Company serves commercial and last-mile fleets, school districts, public and private transportation service companies and colleges and universities to meet the increasing demand for light to heavy-duty electric vehicles.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.